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Castleman’s disease (CD) is an uncommon B-cell lympho-
proliferative disorder characterized by lymph node hyper-
plasia with vascular proliferation. Cutaneous involvement in 
CD is rare. A 65-year-old man presented with a 7-year history 
of gradually developing multiple reddish to violaceous 
indurated plaques on the scalp, trunk, and legs. On physical 
examination, there were palpable enlarged cervical, axillary, 
and inguinal lymph nodes. Laboratory examination revealed 
anemia, thrombocytosis, hyperproteinemia, hypoalbumi-
nemia, and polyclonal hypergammaglobulinemia. An inguinal 
lymph node biopsy and a skin biopsy were performed and 
the patient was diagnosed with the plasma cell type of CD. 
Chemotherapy was started and the lesions have responded 
to treatment. (Ann Dermatol 23(S2) S169∼S174, 2011)
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INTRODUCTION
Castleman’s disease (CD) is an angiofollicular lymphoid 
hyperplasia, or giant lymph node hyperplasia. It is 
characterized by lymph node hyperplasia and vascular 
proliferation
1,2. It was first described in 1956 by Castle-
man et al.
3 as a localized lymphadenopathy that usually 
involves mediastinum or pulmonary hilus resembling 
thymoma. Keller et al.
2 divided CD histologically into 
three types: hyaline-vascular, plasma cell, and mixed type. 





6, and Kaposi sarcoma
7. 
A few cases of CD with cutaneous involvement have been 
reported
8-15. However, there are no reports in the Korean 
literature. Here, we report a case of CD which showed a 
characteristic cutaneous manifestation of multiple 
violaceous plaques with multiple lymphadenopathy that 
responded well to chemotherapy.
CASE REPORT
In May 2008, a 65-year-old man presented with multiple 
violaceous plaques which had developed over the 
previous 7 years. Lesions started as small violaceous 
macules on left axilla, and then spread to the scalp, trunk, 
and legs. They slowly formed confluent indurated pla-
ques. He had pulmonary tuberculosis and tuberculosis 
lymphadenitis which were diagnosed by open lung biopsy 
4 years prior and had been treated with oral medication. 
His family history was non-contributory. On physical 
examination, variable sized reddish to violaceous indu-
rated plaques were observed on his scalp, chest, back, HY Park, et al
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Fig. 1. Multiple reddish to violaceous indurated plaques on both flanks (A, B) and back (C).
Fig. 2. (A) Lymph node biopsy shows multiple follicles with vascular proliferation (H&E, original magnification ×100), (B) Many plasma
cells in the interfollicular area with Russell bodies (arrow) (H&E, ×400).
Fig. 3. Skin biopsy shows multiple lymphoid follicles as nodular
infiltration in the dermis (H&E, ×20).
axilla, and both legs (Fig. 1). Superficial lymph nodes 
were palpable in his neck, axilla, and inguinal areas. A 
previous operative scar was observed on his right side of 
chest. He has been suffered from night sweats for several 
years. However, there were no other systemic symptoms 
such as fever, weight loss, or asthenia. On laboratory 
examination, we found anemia (Hgb 9.4 g/dl, normal 
range: 13.5∼17.5), thrombocytosis (platelet 555×10
3/ 
mm
3, normal range: 150∼350×10
3), increased erythrocyte 
sedimentation rate (ESR) (105 mm/hr, normal range: 0∼
17), hyperproteinemia (total protein 11.4 g/dl, normal 
range: 5.5∼8.0), and polyclonal hypergammaglobuli-
nemia (IgG 4,030 mg/dl, normal range: 614∼1,295; IgM Castleman’s Disease with Cutaneous Involvement Manifestating as Multiple Violaceous Plaques on Entire Body
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Fig. 4. (A) Lymphoid follicles are composed of numerous lymphocytes and plasma cells (H&E, ×400). Immunohistochemical stains 
are positive for CD 20 (B, ×100), CD 79a (C, ×200), and bcl-2 (D, ×200).
547 mg/dl, normal range: 53∼334). Hepatitis B antigen 
and anti-human immunodeficiency virus (HIV) antibody 
were negative. A peripheral blood smear showed a mild 
degree of microcytic hypochromic anemia with rouleaux 
formation and thrombocytosis without definite abnormal 
cells. A bone marrow biopsy revealed a small increase of 
mature plasma cells (approximately 7.3%). There were 
multiple hypermetabolic lymph nodes on his neck, chest, 
and abdomen. Splenomegaly was determined by positron 
emission tomography-computed tomography but there 
was no other internal solid organ involvement. An 
excisional biopsy from the left inguinal lymph node 
showed follicular formation with many lymphocytes and 
dense plasma cells (Fig. 2). A skin biopsy taken from a 
right flank lesion revealed variable sized lymphoid 
follicles in the dermis (Fig. 3) and nodular infiltrates of 
lymphocytes, lymphoplasmacytoid cells, and many plas-
ma cells (Fig. 4A). In the immunohistochemical stain, 
lymphocytes and plasma cells stained positively for CD 
20, CD 79a, CD 5, CD 45RO, and bcl-2 (Fig. 4B∼D). 
CD3 was weakly positive in the reactive T cells. CD10 
and bcl-6 were negative. Kappa and lambda light chain 
were equally stained. 
These findings were consistent with multicentric plasma 
cell type of CD. He was treated with 8 cycles of CHOP 
chemotherapy (cyclophosphamide, adriamycin, vincris-
tine, and prednisone). The size and hypermetabolic acti-
vities of lymph nodes decreased and skin lesions were 
much improved with mild hyperpigmentation. He remains 
healthy 2 years after treatment. 
DISCUSSION
CD is an uncommon B-cell lymphoproliferative disorder. HY Park, et al
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Table 1. Summary of reported cases of Castleman’s disease with cutaneous involvement
Age (yrs)/ Author Clinical features Location Histologic type Sex
 Kubota et al.
8 (1993) 57/M Multiple brownish indurated nodules Face, trunk Plasma cell type
 Skelton and Smith
9 (1998) 72/F Multiple nodules Trunk Plasma cell type
 Klein et al.
10 (2004) 44/F Multiple erythematous and violaceous nodules  Trunk, extremity Plasma cell type
 and plaques
 Kayasut et al.
11 (2006) 71/M Multiple reddish macules and plaques Trunk Plasma cell type
 Ahmed et al.
12 (2007) 42/F Multiple erythematous nodules Face, trunk Plasma cell type
 Okuyama et al.
13  (2007) 45/F Multiple brownish infiltrated nodules and plaques Trunk Plasma cell type
36/F Multiple brownish indurated nodules and plaques Trunk Plasma cell type
 Higashi et al.
14 (2007) 39/F Multiple reddish to brownish plaques Face, trunk Plasma cell type
46/M Multiple reddish to brownish indurated plaques Face, trunk, extremity Plasma cell type
 Tomasini et al.
15 (2009)56/F Multiple erythematous papules and nodules Face, back Hyaline vascular type
 Our case 65/M Multiple reddish to violaceous indurated plaques Scalp, trunk, extremity Plasma cell type
M: male, F: female.
The time to diagnosis the disease is often long, which is 
attributable to clinical polymorphism and poor awareness 
of the disease. CD can occur at any age, even during 
childhood, with peak frequency during adulthood
1. There 
are two clinical forms of CD: unicentric and multicentric
2. 
The onset age of multicentric CD is older than that of 
unicentric CD. There are no gender differences in 
unicentric CD but males have multicentric CD more often 
than females
1,9. The unicentric (solitary) form commonly 
presents as a mass in mediastinum. It can also be found 
outside the thorax (both nodal and extranodal), for 
example on the neck, arm, abdomen, vulva, and 
pericardium
1,16. The multicentric form shows generalized 
lymphadenopathy and various systemic symptoms. It may 
also be associated with POEMS syndrome
1,17. 
Histologic variants of CD are composed of hyaline- 
vascular (90%), plasma cell (10%), and a mixed type
2,12. 
The hyaline-vascular type represents 80 to 90% of all 
cases of the solitary form. The multicentric form consists 
almost entirely of plasma cell type
18. The hyaline-vascular 
type lacks the systemic signs and/or symptoms which are 
commonly associated with plasma cell types
17. Histo-
pathologically, it is characterized by small, concentrically 
whorled, lymphoid follicles surrounded by small lympho-
cytes arranged in a concentric, onion-skin pattern. Exten-
sive capillary proliferation and hyalinized sclerotic colla-
gen are present between follicles
9. The plasma cell type 
shows many systemic signs and/or symptoms including 
fever, anemia, weight loss, loss of appetite, elevated ESR, 
hypergammaglobulinemia, and hypoalbuminemia
18. It 
reveals as well developed hyperplastic secondary lym-
phoid follicles and many plasma cells exist predominantly 
in the interfollicular areas
13. Occassionally, there are 
numerous Russell bodies, deposition of an amorphous 
acidophilic material that probably contains fibrin, and 
immune complexes in the center of follicles
1.
Cutaneous involvement of CD has rarely been reported in 
the multicentric form. Among ten reported cases
8-15, three 
patients were male and seven patients were female. Their 
mean age was 50.8±12.7 yrs (range: 36∼72 yrs). All skin 
lesions manifested as multiple erythematous to brownish 
nodules and plaques predominantly on the back but also 
on the face, trunk, and extremities. Histologic features 
were plasma cell type except in one case. Results are 
summarized in the Table 1. In our case, the patient 
showed multiple reddish to violaceous indurated patches 
on his scalp, chest, back, axilla, and both legs, which is 
similar to other cases. A skin biopsy and a lymph node 
biopsy showed nodular aggregates of many lymphocytes 
and plasma cells with Russell bodies in the dermis. 
Immunohistochemical staining for kappa and lambda light 
chains confirmed the polyclonal nature of the plasma cell 
infiltrate. These findings were compatible with plasma cell 
type CD.
The pathogenesis of CD is still not understood. Interleukin 
(IL)-6 is an important factor in the pathogenesis of CD, 
especially in the multicentric form
12. IL-6 contributes to 
proliferation and maturation of B lymphocytes into mature 
plasma cells and proliferation of blood vessels
19. 
Yoshizaki et al.
20 showed that the cells present in the 
germinal center of the enlarged lymph nodes produce IL-6 
and there is close relationship between the serum levels of 
IL-6 and the clinical symptoms of patients with CD. 
Recently, the incidence of CD in HIV patients has 
increased
10. Epidemiological and polymerase chain 
reaction studies have suggested that human herpes virus 
(HHV)-8 is associated with multicentric CD in all HIV 
positive patients and in almost 50% of HIV negative 
patients
21,22. HHV-8, known as Kaposi sarcoma associated 
herpes virus, also produces a functional analogue of IL-6. 
Although the exact pathogenesis of CD is unknown, 
immune dysregulation of IL-6 may play a key role
10. In Castleman’s Disease with Cutaneous Involvement Manifestating as Multiple Violaceous Plaques on Entire Body
Vol. 23, Suppl. 2, 2011 S173
addition, CD is associated with high levels of IL-10, tumor 
necrosis factor-β, interferon-γ, vascular endothelial growth 
factor, and macrophage colony-stimulating factor
11. In our 
patient, we could not check IL-6 expression or HHV-8 
DNA sequences. 
The differential diagnosis of CD includes angiolymphoid 
hyperplasia with eosinophilia (ALHE), Kimura disease, 
sinus histiocytosis with massive lymphadenopathy, cuta-
neous plasmacytoma, angioimmunoblastic T cell lym-
phoma, primary cutaneous marginal zone lymphoma, and 
primary cutaneous follicular center cell lymphoma
10,15. 
CD can be distinguished from these diseases by combined 
generalized lymphadenopathy, clinical manifestations, 
type and patterns of infiltrate cells, and immunohisto-
chemical stain, especially polyclonal restriction of kappa 
and lambda light chains. 
The treatment differs depending on clinical types. Surgical 
excision is effective for unicentric CD
17. This treatment 
allows full recovery without relapse in almost all cases. 
On the other hand, there is no consensus for the treatment 
of the multicentric type. A variety of approaches, including 
surgery, chemotherapy, radiation therapy, and anti-viral 
therapies, have been attempted
17,18. The treatment of 
choice is a monthly combination chemotherapy such as 
CHOP (cyclophosphamide, vincristine, doxorubicin, pred-
nisone) or AVBD (etoposide, ifosfamide, cisplatin alterna-
ting with doxorubicin, vincristine, bleomycin and dacar-
bazine)
18. Other therapies, such as interferon-α, retinoid 
acid or rituximab or anti-IL-6 antibodies, have been used 
and gave promising results
12,23,24. Generally, the prognosis 
of multicentric CD is poor, but our patient had 8 cycles of 
CHOP chemotherapy and responded well to treatment. 
In conclusion, we report a rare case of cutaneous 
involvement of multicentric CD which had a good 
prognosis. However, further long-term follow up for detec-
tion of recurrence is needed. 
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